Candriam S.C.A. Intercept Pharmaceuticals, Inc. Transaction History

Candriam S.C.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 01, 2019	SELL	$77.77 - $120.68 $6.22 Million - $9.65 Million	-80,000 Closed	0 $0
Q1 2019 May 02, 2019	BUY	$91.83 - $120.68 $7.35 Million - $9.65 Million	80,000 New	80,000 $8.95 Million
Q1 2018 May 09, 2018	SELL	$52.72 - $67.25 $1.69 Million - $2.15 Million	-32,000 Closed	0 $0
Q4 2017 Feb 07, 2018	BUY	$58.2 - $72.76 $989,400 - $1.24 Million	17,000 Added 113.33%	32,000 $1.87 Million
Q3 2017 Nov 03, 2017	BUY	$57.01 - $118.75 $855,150 - $1.78 Million	15,000	15,000 $871,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.